METTL3

LUNGevity Foundation Announces $1.2M in Lung Cancer Workforce Development Research Awards

Retrieved on: 
Wednesday, November 1, 2023
Neoplasm, Radiation, Faculty, Research, NSCLC, Health equity, RNA, ICI, Doctor of Philosophy, Cell, METTL3, Disease, Partnership, Radiation therapy, SCLC, MPH, LCI, Health, Lung cancer, Physician, Workforce, Veteran, Maintenance, Immune system, KIR, Breast cancer, Immunotherapy, Checkpoint, Cancer, Patient, Laboratory, ICIS, Durham, MD, Growth, Development, American Society for Radiation Oncology, LSD1, ASTRO, Survival, FDA, MBA, Treatment of lung cancer, Society, Death, Genomics, Risk, Carcinoma, Diagnosis, LCS, Nursing, Medical imaging, Vaccine

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to continue its multifaceted investment in the thoracic oncology workforce by announcing the recipients of four awards — the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant. 

Key Points: 
  • "Progress in lung cancer research is only possible with a vibrant and diverse thoracic oncology workforce," notes Upal Basu Roy, PhD, MPH, executive director, LUNGevity Research.
  • LUNGevity Foundation is honored to partner with the Lung Cancer Initiative (LCI) to co-fund Dr. LoPiccolo's project on the genomics of young-onset lung cancer.
  • The Lung Cancer Initiative is a leading nonprofit in North Carolina that connects the lung cancer community with the research and medical community.
  • LUNGevity's 2023 VA Research Scholar Award recipient is:
    Lung cancer screening (LCS) provides an important opportunity to find lung cancer early when it is the most treatable.

New Journal of Pharmaceutical Analysis Articles Showcase Promising Therapeutic Candidates for Treating Cancer and Hearing Loss

Retrieved on: 
Wednesday, August 9, 2023
Neuron, DNA, Non-small-cell lung cancer, Hearing loss, JPA, XPO1, Cancer, Quality of life, Research, NSCLC, Cisplatin, Liver, DNA repair, HIV disease progression rates, Patient, Apoptosis, Cell cycle, METTL3, Dick's Picks Volume 13, Ataxia–telangiectasia, Leukemia, Kinetics, ATR, PRMT5, Pharmaceutical industry

XI'AN, China, Aug. 9, 2023 /PRNewswire/ -- Although cancer treatment has advanced significantly over the last decade, some fairly common cancers remain extremely difficult to treat. Besides, some chemotherapeutics or anti-cancer drugs can have serious, irreversible side-effects. The latest issue of the JPA features three articles that highlight novel treatment strategies based on cutting-edge research on cancer and chemotherapeutic drug-induced adverse events.

Key Points: 
  • The latest issue of the JPA features three articles that highlight novel treatment strategies based on cutting-edge research on cancer and chemotherapeutic drug-induced adverse events.
  • The first study reports a new approach to prevent hearing loss induced by the widely used chemotherapeutic drug "cisplatin".
  • The article was available online in April 2023 and published in Volume 13, Issue 6 in June 2023 .
  • A better understanding of the role of PRMT5 in hearing loss could help scientists develop effective hearing protection drugs and prevent this unwanted side-effect.

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

Retrieved on: 
Tuesday, August 8, 2023
Peter MacCallum Cancer Centre, Enzyme, Cancer Discovery (journal), Therapy, Standard of care, Patient, RNA, RME, METTL3, Pharmaceutical industry, Vaccine, Nature

CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it has published a scientific manuscript in the internationally recognised scientific journal Cancer Discovery.

Key Points: 
  • Using pre-clinical cancer models, the study shows that pharmacological inhibition of METTL3 induces double-stranded RNA formation and a profound cell-intrinsic interferon response that potentiates T-cell killing of cancer cells.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics and joint senior author of the study, said, "We are pleased to share this new data with the scientific community.
  • Our study identifies a novel therapeutic mechanism triggered by METTL3 inhibition that opens a significant opportunity for METTL3 inhibitors in immuno-oncology.
  • Andrew A Guirguis, Yaara Ofir-Rosenfeld et al, 2023, Cancer Discovery (advanced online publication) https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.C...

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

Retrieved on: 
Tuesday, August 8, 2023
Peter MacCallum Cancer Centre, Enzyme, Cancer Discovery (journal), Therapy, Standard of care, Patient, RNA, RME, METTL3, Pharmaceutical industry, Vaccine, Nature

CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it has published a scientific manuscript in the internationally recognised scientific journal Cancer Discovery.

Key Points: 
  • Using pre-clinical cancer models, the study shows that pharmacological inhibition of METTL3 induces double-stranded RNA formation and a profound cell-intrinsic interferon response that potentiates T-cell killing of cancer cells.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics and joint senior author of the study, said, "We are pleased to share this new data with the scientific community.
  • Our study identifies a novel therapeutic mechanism triggered by METTL3 inhibition that opens a significant opportunity for METTL3 inhibitors in immuno-oncology.
  • Andrew A Guirguis, Yaara Ofir-Rosenfeld et al, 2023, Cancer Discovery (advanced online publication) https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.C...

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

Retrieved on: 
Wednesday, January 25, 2023
Therapy, Survival, Venetoclax, AML, Conference, Poster, AACR, RME, METTL3, Acute myeloid leukemia, American Association for Cancer Research, FDA, RNA, Cancer, Enzyme, Animal, BCL2, Myelodysplastic syndrome, Patient, Clinical trial, Publication, Pharmaceutical industry

The new data in AML preclinical models was presented at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, hosted in Austin, Texas on the 23-25 January.

Key Points: 
  • The new data in AML preclinical models was presented at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, hosted in Austin, Texas on the 23-25 January.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "These studies provide evidence for the utility of METTL3 inhibitors as a new therapeutic approach to treat AML.
  • Jerry McMahon, Chief Executive Officer & President of STORM Therapeutics, said: "We are excited to present this new data with patient-derived tumor samples supporting the future clinical development of STC-15 in AML.
  • Details of the conference and presented poster are as follow:
    The Poster and Abstract are available on the STORM Therapeutics website: Publications .

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

Retrieved on: 
Wednesday, January 25, 2023
Therapy, Survival, Venetoclax, AML, Conference, Poster, AACR, RME, METTL3, Acute myeloid leukemia, American Association for Cancer Research, FDA, RNA, Cancer, Enzyme, Animal, BCL2, Myelodysplastic syndrome, Patient, Clinical trial, Publication, Pharmaceutical industry

The new data in AML preclinical models was presented at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, hosted in Austin, Texas on the 23-25 January.

Key Points: 
  • The new data in AML preclinical models was presented at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, hosted in Austin, Texas on the 23-25 January.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "These studies provide evidence for the utility of METTL3 inhibitors as a new therapeutic approach to treat AML.
  • Jerry McMahon, Chief Executive Officer & President of STORM Therapeutics, said: "We are excited to present this new data with patient-derived tumor samples supporting the future clinical development of STC-15 in AML.
  • Details of the conference and presented poster are as follow:
    The Poster and Abstract are available on the STORM Therapeutics website: Publications .

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

Retrieved on: 
Thursday, October 20, 2022
Degenerative disease, Society for Immunotherapy of Cancer, Merck, Molecular biology, Therapy, Government, Cancer immunotherapy, Conference, Global Partnership for Education, SITC, ENA, Patient, Annual Meetings of the International Monetary Fund and the World Bank Group, Drug development, METTL3, RNA, Enzyme, Annual general meeting, RME, Immunotherapy, Inflammation, Cancer, University, Trial of the century, Drug discovery, STORM, Industry, CEO, Merck Group, CNS, Environment, FTI, FDA, Human, IP Group, Pharmaceutical industry, Vaccine, IND

CAMBRIDGE, England, Oct. 20, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting novel data on its lead program STC-15, a first-in-class clinical candidate, at the upcoming 34th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium and the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Dr. Jerry McMahon, CEO of STORM Therapeutics commented:"We are delighted to be presenting data from our first-in-class clinical candidate STC-15, an orally bioavailable, highly selective METTL3 inhibitor at these two scientific conferences.
  • There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.
  • STORM's lead program STC-15 is a first-in-class clinical candidate and will be the first inhibitor of RNA modification to enter clinical development in humans.
  • In addition, the meeting includes updates on major national and international initiatives coming from academia, government, and industry, as well as important society projects.

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

Retrieved on: 
Thursday, October 20, 2022
Degenerative disease, Society for Immunotherapy of Cancer, Merck, Molecular biology, Therapy, Government, Cancer immunotherapy, Conference, Global Partnership for Education, SITC, ENA, Patient, Annual Meetings of the International Monetary Fund and the World Bank Group, Drug development, METTL3, RNA, Enzyme, Annual general meeting, RME, Immunotherapy, Inflammation, Cancer, University, Trial of the century, Drug discovery, STORM, Industry, CEO, Merck Group, CNS, Environment, FTI, FDA, Human, IP Group, Pharmaceutical industry, Vaccine, IND

CAMBRIDGE, England, Oct. 20, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting novel data on its lead program STC-15, a first-in-class clinical candidate, at the upcoming 34th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium and the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Dr. Jerry McMahon, CEO of STORM Therapeutics commented:"We are delighted to be presenting data from our first-in-class clinical candidate STC-15, an orally bioavailable, highly selective METTL3 inhibitor at these two scientific conferences.
  • There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.
  • STORM's lead program STC-15 is a first-in-class clinical candidate and will be the first inhibitor of RNA modification to enter clinical development in humans.
  • In addition, the meeting includes updates on major national and international initiatives coming from academia, government, and industry, as well as important society projects.